Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Universal Vaccine Platform

The University of Texas Medical Branch at Galveston’s Universal Vaccine Platform

Orange County, CA - October 10th 2018 -  Once germs enter the human body and they start to reproduce, the immune system distinguishes them as an intruder attacking the body.  It responds by making proteins called “antibodies”. The antibodies help destroy the germs that make you feel sick. However, they’re not able to act fast enough to prevent illness; instead, it eliminates the attacking germs and helps you get well. 

Antibodies remain in the bloodstream. If the infection comes back again, even after many years, it will protect you. Since the infection has already been in your system, they are experienced at fighting these particular germs, and they destroy them before they have a chance to make you sick.

Vaccines offer a solution to this problem by helping your body develop immunity, without getting sick first. They’re made from the same germs (or parts of them) that cause disease, but the germs in Vaccines are weakened or killed, so they are unable to make you ill.

Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contamination. It’s required for vaccines to be kept refrigerated during the transportation from manufacturers to health care clinics. In hotter regions where cold storage is required, vaccine costs can contribute to 80% of the vaccine cost.

Researchers at the University of Texas Medical Branch at Galveston have developed a cheaper way to produce vaccines that cuts the costs of vaccine production, and storage by up to 80 percent without decreasing safety or effectiveness.

"The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development. Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens,"said UTMB's Pei-Yong Shi, professor in the department of biochemistry and molecular biology.

The research team developed a live-attenuated Zika vaccine, (weakened version of the virus) in DNA form. Once it is deposited in our body, it sends the vaccine to our cells, leading to antibody production, and other protective immunity. Proceeding with this method means there is no need to manufacture the vaccine in cell culture, or eggs at factories. DNA molecules are shelf stable; the vaccine will not expire with warm temperatures, and can be stored at room temperature for years. “This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said.

The team will continue testing this Zika vaccine platform and apply it to other viruses.

Contact Ampronix:

Email: [email protected] 

International Sales: +1 949-273-8000

Domestic Sales: 1800-400-7972 for US and Canada

Follow Us:

FacebookTwitterLinkedIn

Share This Article:

View our Product Catalog Online Here

 

About Ampronix

Ampronix is a renowned authorized master distributor of the medical industry's top brands as well as a world-class manufacturer of innovative technology. Since 1982, Ampronix has been dedicated to meeting the growing needs of the medical community with its extensive product knowledge, outstanding service, and state-of-the-art repair facility. Ampronix prides itself on its ability to offer tailored, one-stop solutions at a faster and more cost-effective rate than other manufacturers. Ampronix is ISO 13485:2003, and ANSI/ESD S20.20-2014 certified.

 



This post first appeared on Ampronix Medical News, please read the originial post: here

Share the post

Universal Vaccine Platform

×

Subscribe to Ampronix Medical News

Get updates delivered right to your inbox!

Thank you for your subscription

×